Claims
- 1. A substantially pure glycopeptide having the following properties:
- (a) has a molecular weight of about 93,000 daltons as determined by SDS-PAGE technique under reducing conditions,
- (b) is a subunit member of the gCI complex of human cytomegalovirus,
- (c) contains a B cell or T cell epitode which is not present in another gCI complex subunit glycopeptide having a molecular weight of about 55,000 daltons as determined by SDS-PAGE technique under reducing conditions,
- (d) associated by at least one disulfide bond with other gCI complex subunit glycopeptides having molecular weights of about 130,000 daltons and about 55,000 dalton as determined by SDS-PAGE under reducing conditions,
- (e) associated with said gCI complex subunit glycopeptides in the gCI complex under non-reducing conditions.
- 2. A glycopeptide according to claim 1 wherein the epitope is a T cell epitope.
- 3. A glycopeptide according to claim 1 wherein the epitope is a B cell epitode.
- 4. The glycopeptide of claim 3 which does not react with a monoclonal antibody selected from the group consisting of 41C2, 26B11, 39E11 9B7, 18F9, 34G7, 11B4, and 23B11, and said monoclonal antibody does react with the said about 55,000 dalton glycoprotein.
- 5. The glycopeptide of claim 1 wherein said glycopeptide reacts with human cytomegalovirus seropositive convalescent sera.
- 6. A vaccine against human cytomegalovirus comprising an immunologically effective amount of the glycopeptide of claim 1 in combination with a pharmaceutically acceptable carrier.
- 7. A method for raising the titer of an antibody against human cytomegalovirus in the blood of a mammal, comprising the step of administering to the mammal a vaccine of claim 6.
- 8. A method for inducing T helper cell (T.sub.h) and T cytotoxic cell response against human cytomegalovirus comprising administering to the patient a vaccine of
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. Pat. application Ser. No. 07/083,502, filed Aug. 7, 1987, which is in turn a continuation-in-part of U.S. Pat. application Ser. No. 06/933,789, filed Nov. b 24, 1986, abandoned, and is also a continuation-in-part of U.S. Pat. application Ser. No. 07/214,302, filed July 1, 1988 (abandoned). The disclosures of all three applications are incorporated by reference herein.
STATEMENT REGARDING FEDERALLY-FUNDED RESEARCH
This invention was made with government support under Department of Health and Human Services Grant No. HDMC 5 PO1GHD19937-03 GT. The government may have certain rights in the invention.
Foreign Referenced Citations (2)
Number |
Date |
Country |
0122841 |
Mar 1984 |
EPX |
0236145 |
Sep 1987 |
EPX |
Non-Patent Literature Citations (4)
Entry |
Journal of General Virology, vol. 69, 1988, SGM (GB), D. R. Gretch et al.: "Characterization of a Human Cytomegalovirus Glycoprotein Complex (gCI)", pp. 1205-1215. |
Virology, vol. 167, 1988, Academic Press, Inc., R. R. Spaete et al.: "Human Cytomegalovirus Strain Towne Glycoprotein B 1s Processed by Proteolytic Cleavage", pp. 207-225. |
The EMBO Journal, vol. 5, No. 11, 1986, IRL Press Limited, (Oxford, GB), M. P. Cranage et al.: "Identification of the Human Cytomegalovirus Glyprotein B. Gene and Induction of Neutralizing Antibodies via its Expression in Recombinant Vaccinia Virus", pp. 3057-3063. |
Journal Exp. Medicine, vol. 168, Sep. 1988, The Rockefeller University Press, L. K. Borysiewicz et al.: "Human Cytomegalovirus-Specific Cytotoxic T. Cells", pp. 919-931. |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
83502 |
Aug 1987 |
|
Parent |
933789 |
Nov 1986 |
|
Parent |
214302 |
Jul 1988 |
|